Table 1 In vitro synergistic... | American Society of Hematology

Table 1

In vitro synergistic cytotoxicity of dasatinib with conventional MM therapeutics

	Dasatinib, nM	MM tumor/EC cocultures		MMECs
	Dasatinib, nM	Fa	CI	Fa	CI
Bortezomib
2.5 nM	5	0.523	0.203	0.702	0.313
5 nM	5	0.754	0.164	0.736	0.258
2.5 nM	10	0.695	0.103	0.786	0.126
5 nM	10	0.776	0.096	0.813	0.106
Thalidomide
5 μM	5	0.643	0.406	0.654	0.245
10 μM	5	0.712	0.464	0.956	0.482
5 μM	10	0.782	0.589	0.93	0.123
10 μM	10	0.775	0.548	0.914	0.221
Melphalan
0.5 μM	5	0.542	0.502	0.501	0.912
2 μM	5	0.837	0.576	0.574	0.462
0.5 μM	10	0.893	0.786	0.513	0.775
2 μM	10	0.97	0.568	0.533	0.664
Prednisone
40 μg/mL	5	0.603	0.398	0.647	0.936
400 μg/mL	5	0.652	0.445	0.614	0.547
40 μg/mL	10	0.624	0.243	0.816	0.348
400 μg/mL	10	0.732	0.255	0.902	0.428

	Dasatinib, nM	MM tumor/EC cocultures		MMECs
	Dasatinib, nM	Fa	CI	Fa	CI
Bortezomib
2.5 nM	5	0.523	0.203	0.702	0.313
5 nM	5	0.754	0.164	0.736	0.258
2.5 nM	10	0.695	0.103	0.786	0.126
5 nM	10	0.776	0.096	0.813	0.106
Thalidomide
5 μM	5	0.643	0.406	0.654	0.245
10 μM	5	0.712	0.464	0.956	0.482
5 μM	10	0.782	0.589	0.93	0.123
10 μM	10	0.775	0.548	0.914	0.221
Melphalan
0.5 μM	5	0.542	0.502	0.501	0.912
2 μM	5	0.837	0.576	0.574	0.462
0.5 μM	10	0.893	0.786	0.513	0.775
2 μM	10	0.97	0.568	0.533	0.664
Prednisone
40 μg/mL	5	0.603	0.398	0.647	0.936
400 μg/mL	5	0.652	0.445	0.614	0.547
40 μg/mL	10	0.624	0.243	0.816	0.348
400 μg/mL	10	0.732	0.255	0.902	0.428